Home » Topics » Cancer, BioWorld Science

Cancer, BioWorld Science
RSS

Bayer and Onyx terminate clinical phase III Nexavar study in NSCLC

Feb. 19, 2008

Recent patents describe novel compounds for the treatment of cancer

Feb. 19, 2008

Qiagen and Center for Molecular Medicine research molecular diagnostic markers

Feb. 15, 2008

FDA grants fast track status to Boehringer Ingelheim's BIBW-2992 for NSCLC

Feb. 15, 2008

AEterna Zentaris commences dosing in phase II trial of cancer drug AEZS-108

Feb. 14, 2008

Alocrest demonstrates preliminary efficacy and tolerability in phase I clinical trial

Feb. 14, 2008

Clavis Pharma successfully completes Elacyt phase I clinical trial in hematology

Feb. 14, 2008

Decapeptyl 6-month formulation shows similar efficacy to 3-month triptorelin

Feb. 13, 2008

Recent patents impart novel treatment options for cancer

Feb. 13, 2008

Pro-Pharmaceuticals reports encouraging data from phase II trial of Davanat in colorectal cancer

Feb. 13, 2008

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 9, 2026.
Hengrui discovers new Nav1.8 blockers
BioWorld Science
Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...
Hematopoietic stem cell research points to leukemia’s early roots
BioWorld Science
Hematopoietic stem cell (HSC) research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...
Infinimmune presents preclinical data on anti-IL-22 antibody for atopic dermatitis
BioWorld Science
Infinimmune Inc. has recently presented results at the annual American Academy of Dermatology conference regarding their anti-IL-22 antibody IFX-101 for the...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026